Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics, Inc. and Astellas Pharma Inc. announced dosing of the first patient in EV-201, a registrational phase 2 clinical...